Get the Stockscreener App
22.25
1.71%
0.375
Structure Therapeutics Inc Adr stock is traded at $22.25, with a volume of 612.75K.
It is up +1.71% in the last 24 hours and down -42.86% over the past month.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.
See More
Previous Close:
$21.88
Open:
$21.89
24h Volume:
612.75K
Relative Volume:
0.40
Market Cap:
$1.59B
Revenue:
Net Income/Loss:
$-170.73M
P/E Ratio:
-8.2668
EPS:
-2.6921
Net Cash Flow:
$-159.70M
1W Performance:
-13.30%
1M Performance:
-42.86%
6M Performance:
-58.98%
1Y Performance:
-23.86%
1-Day Range:
$21.81
$22.61
1-Week Range:
$21.55
$26.15
52-Week Range:
$21.55
$94.90
Structure Therapeutics Inc Adr Stock (GPCR) Company Profile
Name
Structure Therapeutics Inc Adr
Sector
Industry
Phone
(650) 457-1978
Address
601 GATEWAY BLVD SUITE 900, SOUTH SAN FRANCISCO
Compare GPCR vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GPCR
Structure Therapeutics Inc Adr
|
22.25 | 1.59B | 0 | -170.73M | -159.70M | -2.6921 |
VRTX
Vertex Pharmaceuticals Inc
|
510.13 | 129.30B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
237.70 | 94.90B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
801.21 | 82.49B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
848.03 | 53.33B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
370.95 | 41.96B | 5.76B | 514.49M | 1.10B | 4.4813 |
Structure Therapeutics Inc Adr Stock (GPCR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-27-26 | Initiated | Canaccord Genuity | Buy |
| Mar-26-26 | Initiated | Wolfe Research | Peer Perform |
| May-02-25 | Initiated | Citigroup | Buy |
| Feb-28-25 | Initiated | William Blair | Outperform |
| Jan-08-25 | Initiated | Stifel | Buy |
| Dec-04-24 | Initiated | H.C. Wainwright | Buy |
| Sep-23-24 | Initiated | Morgan Stanley | Overweight |
| May-21-24 | Initiated | JP Morgan | Overweight |
| Apr-09-24 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-19-23 | Initiated | JMP Securities | Mkt Outperform |
| Jul-27-23 | Initiated | Piper Sandler | Overweight |
| May-25-23 | Resumed | Jefferies | Buy |
| Feb-28-23 | Initiated | BMO Capital Markets | Outperform |
| Feb-28-23 | Initiated | Guggenheim | Buy |
| Feb-28-23 | Initiated | Jefferies | Buy |
| Feb-28-23 | Initiated | SVB Securities | Outperform |
View All
Structure Therapeutics Inc Adr Stock (GPCR) Latest News
Novo Down 11% in a Month: How Should Investors Approach the Stock Now? - Zacks Investment Research
LLY Stock Down 2% in 3 Months: Is the Dip a Buying Opportunity? - Zacks Investment Research
Analysts Offer Insights on Healthcare Companies: Autolus Therapeutics (AUTL) and Rocket Pharmaceuticals (RCKT) - The Globe and Mail
Structure Therapeutics (GPCR) Slides 5.23% to $33.23, Pulling Back Toward Key Support at $31.57FRAMA Signal - https://www.dars.gov.et/
Can Novo's Rare Disease Pipeline Add a New Growth Pillar Beyond GLP-1? - Zacks Investment Research
Structure Therapeutics (NasdaqGM:GPCR) Stock Forecast & Analyst Predictions - Simply Wall Street
Form 4 Structure Therapeutics Inc ADR For: 22 September By Investing.com - Investing.com Canada
Form 4 Structure Therapeutics Inc ADR For: 22 September By Investing.com - Investing.com India
Structure Therapeutics (GPCR) CMO sells shares under preset plan - Stock Titan
Structure Therapeutics Inc. (GPCR) Stock Price, News, Quote & History - Yahoo! Finance Canada
Structure Therapeutics Inc.American Depositary Shares (Nasdaq:GPCR) Price Chart - The Chronicle-Journal
Price-Driven Insight from (GPCR) for Rule-Based Strategy - Stock Traders Daily
Structure Therapeutics at Cantor conference: oral obesity push advances By Investing.com - Investing.com Canada
Structure Therapeutics at Cantor conference: oral obesity push advances - Investing.com
Structure Therapeutics Advances ACCG-2671 with 3.3% Weight Loss; Aleniglipron Hits 16.2% Reduction (NASDAQ: GPCR) - Kalkine Media
Analysts Are Bullish on These Healthcare Stocks: enGene Holdings (ENGN), Structure Therapeutics, Inc. Sponsored ADR (GPCR) - The Globe and Mail
Structure Therapeutics stock price target maintained at $70 by H.C. Wainwright - Investing.com Canada
Citizens reiterates Structure Therapeutics stock rating on trial data - investing.com
Citizens reiterates Structure Therapeutics stock rating on trial data By Investing.com - Investing.com Canada
Citizens reiterates Structure Therapeutics stock rating on trial data By Investing.com - Investing.com UK
Structure Therapeutics (GPCR) Shares Slide After Obesity Drug Tr - GuruFocus
Jefferies raises Structure Therapeutics stock target on amylin data By Investing.com - Investing.com Canada
Novo Nordisk's Semaglutide Meets Goal in Pediatric Obesity Study - Zacks Investment Research
Structure Therapeutics Reports Positive ACCG-2671 Early Trial Results - TipRanks
Oral obesity drug shows double-digit weight loss as Structure Therapeutics (NASDAQ: GPCR) advances Phase 3 trials - Stock Titan
A weight-loss pill cut body weight 16.2% in 72 weeks - Stock Titan
Analysts Conflicted on These Healthcare Names: Kymera Therapeutics (KYMR) and vTv Therapeutics (VTVT) - theglobeandmail.com
Morgan Stanley’s conference is one of three Structure Therapeutics plans to join in September - Stock Titan
Structure Therapeutics (GPCR) CSO sells 5,939 ADSs under preset plan - Stock Titan
Barinthus Biotherapeutics advances court-approved merger, Nasdaq exit - The Globe and Mail
(GPCR) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
NVO vs. GPCR: Which Obesity Stock Is the Better Buy Right Now? - Eastern Progress
Analysts Are Bullish on Top Healthcare Stocks: Enliven Therapeutics (ELVN), Argenx Se (ARGX) - theglobeandmail.com
Structure (GPCR) Watch: Finishes 6.67% Down at $50.52 in the Current Update; Range Check: Support at $47.99 and Resistance at $53.05 Frame the Range at the CloseMomentum ETF - dars.gov.et
Can Awiqli Help Novo Nordisk Build a New Growth Engine Beyond GLP-1s? - Eastern Progress
Handelsbanken Fonder AB Purchases Shares of 19,400 Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Structure (GPCR) Watch: Finishes 6.67% Down at $50.52 in the Current Update; Range Check: Support at $47.99 and Resistance at $53.05 Frame the Range at the CloseComposite Profile - www.dars.gov.et
Structure Therapeutics (GPCR) exec sells 3,939 ADSs under plan - Stock Titan
Structure (GPCR) Earnings Reading: EPS Comes in Below Forecast in the Current Update; Market Response: The Stock Gains 1.12% in the Latest SessionRevenue Warning Signal - dars.gov.et
How Does LLY's Q2 GLP-1 Portfolio Performance Stack Up Against NVO's? - TradingView
Structure (GPCR) Earnings Reading: EPS Comes in Below Forecast in the Current Update; Market Response: The Stock Gains 1.12% in the Latest SessionRevenue Guidance Update - careplusvn.com
Structure (GPCR) Earnings Reading: EPS Comes in Below Forecast in the Current Update; Market Response: The Stock Gains 1.12% in the Latest SessionNegative Surprise Momentum - dars.gov.et
Structure (GPCR) Earnings Reading: EPS Comes in Below Forecast in the Current Update; Market Response: The Stock Gains 1.12% in the Latest SessionShare Dilution Risk - dars.gov.et
Structure (GPCR) Earnings Reading: EPS Comes in Below Forecast in the Current Update; Market Response: The Stock Gains 1.12% in the Latest SessionTax Rate Impact - dars.gov.et
LLY Up Around 6% Post Robust Q2 Results: Buy, Sell or Hold the Stock? - TradingView
Structure Therapeutics (NASDAQ:GPCR) Rating Increased to Sell at Wall Street Zen - MarketBeat
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Analysts Have Conflicting Sentiments on These Healthcare Companies: Candel Therapeutics (CADL), LENSAR (LNSR) and Pyxis Oncology (PYXS) - The Globe and Mail
Can Novo Nordisk's GLP-1 Pill Momentum Offset LLY's Growing Edge? - TradingView
LLY's Foundayo Posts $98M in Q2 Sales: What's Next for the Oral GLP-1? - TradingView
Structure Therapeutics Inc Adr Stock (GPCR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Structure Therapeutics Inc Adr Stock (GPCR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Lin Xichen | CHIEF SCIENTIFIC OFFICER |
Sep 01 '26 |
Option Exercise |
0.34 |
17,817 |
6,058 |
246,777 |
| Lin Xichen | CHIEF SCIENTIFIC OFFICER |
Aug 18 '26 |
Option Exercise |
0.34 |
11,817 |
4,018 |
240,777 |
| Lin Xichen | CHIEF SCIENTIFIC OFFICER |
Aug 04 '26 |
Option Exercise |
0.34 |
11,817 |
4,018 |
240,777 |
| Lin Xichen | CHIEF SCIENTIFIC OFFICER |
Jul 14 '26 |
Option Exercise |
0.34 |
23,634 |
8,036 |
252,594 |
| Lin Xichen | CHIEF SCIENTIFIC OFFICER |
Jun 25 '26 |
Option Exercise |
0.34 |
23,634 |
8,036 |
252,594 |
| XICHEN LIN | Officer |
Jun 25 '26 |
Proposed Sale |
48.16 |
35,512 |
1,710,258 |
0 |
1.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):